

Geneesmiddelen waarvoor voorafgaand aan de behandeling een machtiging moet worden aangevraagd per 1-1-2024

| ATC | Geneesmiddelengroep | Geneesmiddelen | Indicatie Indien onderstaand een indicatie is gevuld, hoeft u alleen bij deze indicatie de machtiging aan te vragen. Indien er geen indicatie is gevuld dan altijd, dus bij alle indicaties, een machtiging aanvragen. |
|---------------------------|--------------------------------|---|---|
| L01EF | CDK4/6 remmer | Abemaciclib, palbociclib, ribociclib | |
| L02B | Antihormonen | Abirateron, apalutamide, enzalutamide, estramustine | |
| I04AB | TNF- alfa remmers | adalimumab, certolizumab pegol, etanercept, golimumab, infliximab | Uveitis, zeldzame aandoeningen |
| D02BB02 | Alfa-MSH analoga | afamelanotide | EPP |
| S01LA | Angiogeneseremmers | aflibercept, brolucizumab, faricimab, ranibizumab, | Macula aandoeningen |
| L01XX35 | Anagrelide/ overige oncolytica | anagrelide | hematologie (incl kinderen) |
| LO4AA36 | Anti-CD20 | ocrelizumab | |
| J04AK05 | antimycobacteriele middelen | bedaquiline | |
| L01EX12 | anti-NTRK | larotrectinib | |
| N07XX12, A16AX18, M09AX07 | Antisense oligonucleotide | patisiran, lumasiran, nusinersen | weesgeneesmiddel(len) |
| B01AB02 | Antitrombine 3 | antitrombine III | |
| B01AX | antitrombotica | caplacizumab, defibrotide | |
| J05AX18, J05AB, J05AX10 | antivirale middelen | letermovir, maribavir, remdesivir | |
| L01XX27 | arseeentrioxide | arseeentrioxide | |
| LO4AA26 | BAFF remmer | belimumab | |

| | | | |
|---|---|---|--|
| L01XX52 | BCL-2 remmers | venetoclax | |
| M03AX01 | botuline toxine | botuline toxine | |
| L01EE (MEK); L01EC(BRAF) | BRAF/MEK remmers | binimetinib, cobimetinib, dabrafenib, encorafenib, trametinib, vemurafenib | |
| L04AA34 | CD52 | alemtuzumab | |
| R07AX | CFTR-regulator | Ivacaftor, ivacaftor met lumacaftor, ivacaftor met tezacaftor, ivacaftor met tezacaftor en elexacaftor | |
| L01A, L01B, L01C, L01D, L01XD, L01XF, L01XX | Chemo | aminolevulinezuur, amsacrine, asparaginase, azacitidine, bendamustine, bexaroteen, bleomycine, busulfan, cabazitaxel, capecitabine, chloorambucil, chloormethine, cisplatine, clofarabine, cyclofosfamide, cytarabine, decitabine, docetaxel, doxorubicine, epirubicine, eribuline, etoposide, fludarabine, gemcitabine, hydroxycarbamide, idarubicine, irinotecan, lomustine, melfalan, methylaminolevulinaat, mitomycine, mitotaan, mitoxantron, nelarabine, oxaliplatin, paclitaxel, panobinostat, pegaspargase, pemetrexed, pixantron, procarbazine, tegafur, temoporfine, temozolomide, teniposide, thiotepa, topotecan, trabectedine, tretionoïne, trifluridene, vinblastine, vincristine, vinorelbine, | |
| L01XX70, L01XX71 | chimere Antigen Receptor (CAR) T-cel therapie | axicabtagene ciloleucel, tisagenlecleucel, | |
| L04AA | Complementremmers | eculizumab, pegcetacoplan, ravulizumab, sutimlimab, | |
| L04AA28 | CTLA-4 remmer | belatacept | |
| L03AX16 | CXCR4-antagonisten | plerixafor | |
| V03AF09 | detoxificantia | glucarpidase | |
| A16AX10, B03XA05 | enzyme remmers | eliglustat, roxadustat | |
| A16AB | enzymen | agalsidase alfa, agalsidase bèta, alglucosidase alfa, asfotase alfa, cerliponase alfa, elosulfase alfa, galsulfase, idursulfase, imiglucerase, laronidase, sebelipase alfa, velaglucerase alfa | Agalsidase alfa kwaliteitsvragen; http://www.huisarts.be/attestnl/replagal.pdf |
| B02BD04 | Factor IX | Factor IX | |

| | | | |
|---|--------------------------------------|--|-----------------------------|
| B02BD02 | Factor VIII | Factor VIII, susoctocog alfa, von willebrand factor, protrombinecomplex geactiveerd | |
| B02BD07 | Factor XIII | Factor XIII | |
| H01CA01, G03G | fertiliteitshormonen, gonadotrofinen | gonadoreline, combinatiepreparaten, corifollitropine alfa, follitropine alfa, follitropine beta, follitropine delta, menopauzegonadotrofine, urofollitropine | |
| M05BX05 | FGF23 remmer | burosumab | |
| A16AB21, M09AX09, S01XA27 | gentherapie | atidarsageen autotemsel, onasemnogene abeparvovec, voretigeeen neparvovec | |
| R03DX05 | IgE remmer | omalizumab | neuspoliepen |
| L01XC, L01FA, L01XL, L01FD, L01FC, L01FF, L01XY, L01FG, L01FX, L01FB, L01FE | immuuntherapie | aflibercept, amivantamab, atezolizumab, avelumab, bevacizumab, blinatumomab, brentuximabvedotine, cemiplimab, cetuximab, daratumumab, dinutuximab beta, durvalumab, elotuxumab, enfortumab vedotine, gemtuzumab ozogamicin, inotuzumab ozogamicine, ipilimumab, isatuximab, mogamulizumab, nivolumab, obinutuzumab, panitumumab, pembrolizumab, pertuzumab, pertuzumab met trastuzumab, polatuzumab vedotine, ramucirumab, rituximab, talimogeen laherparepvec, trastuzumab, trastuzumab emtansine, trastuzumab deruxtecan | oncologie |
| L04AA51 | Interferon remmers | Anifrolumab | |
| D11AH, L04AC, R03DX | interleukineremmers | anakinra, benralizumab, bimekizumab, brodalumab, canakinumab, dupilumab, guselkumab, ixekizumab, mepolizumab, reslizumab, risankizumab, sarilumab, satralizumab, secukinumab, siltuximab, spesolimab, tezepelumab, tildrakizumab, tocilizumab, tralokinumab, ustekinumab | maligniteiten, hematologie. |
| D11AH08, L04AA37, L04AA45, L04AA29, L04AA44, | JAK remmers | abrocitinib, baricitinib, filgotinib, tofacitinib, upadacitinib, | |
| M09AX02 | kraakbeencellen | kraakbeencellen, autoloog. | |
| L03AX15 | MDP derivaat | mifamurtide | |

| | | | |
|--|-----------------------------|--|--------------------|
| LO4AX08 | mesenchymale stamcellen | darvadstrocel | |
| LO1EG | m-TOR remmers | everolimus, temsirolimus | |
| VO3AX04 | opioïdreceptor agonisten | difelikefaline | |
| LO1XK | PARP-remmers | niraparib, olaparib, rucaparib, talazoparib | |
| LO1EM01 | PI3K remmers | idelalisib | |
| LO1XG | proteasoomremmer | bortezomib, carfilzomib, ixazomib | |
| LO1EM03, LO1EX18, LO1EM04, LO1EX14, LO1EX22, LO1EX21, LO1EH03 | proteïne kinase remmers | alpelisib, avapritinib, duvelisib, entrectinib, selpercatinib, tepotinib, tucatinib | |
| V10XX | radiofarmaca | lutetium 177 LU Oxodotreotide, lutathera, radium 223 RA dichloride, | |
| LO1XJ | SMO-remmers | sonidegib, vismodegib | basaalcelcarcinoom |
| S01XA19 | Stamcellen | Limbale stamcellen, autoloog | |
| LO4AX | thalidomide derivaten | lenalidomide, pomalidomide | |
| LO1E | TKI | acalabrutinib, afatinib, alectinib, asciminib, axitinib, bosutinib, brigatinib, cabozantinib, ceritinib, crizotinib, dacomitinib, dasatinib, erlotinib, fedratinib, gefinitib, gilteritinib, ibrutinib, imatinib, lapatinib, lenvatinib, lorlatinib, midostaurine, nilotinib, nintedanib, osimertinib, pazopanib, ponatinib, regorafenib, ruxolitinib, sorafenib, sunitinib, tivozanib, vandetanib, zanubrutinib | |
| LO4AA | Specifieke immunoglobulinen | lymfocytenimmunoglobuline, thymocytenimmunoglobuline | |